News
NTLA
--
0.00%
--
Press Release: Intellia Therapeutics Names Georgia Keresty, Ph.D., M.P.H., to Board of Directors
Dow Jones · 11h ago
The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 7)
Benzinga · 4d ago
Intellia Therapeutics Inc (NTLA) EVP, General Counsel Jose E Rivera Sold $4.2 million of Shares
GuruFocus News · 04/05 09:48
Intellia Therapeutics Inc (NTLA) EVP, General Counsel Jose E Rivera Sold $4.2 million of Shares
GuruFocus News · 04/05 04:15
Intellia Therapeutics Stock Is Believed To Be Significantly Overvalued
GuruFocus News · 03/31 18:13
Intellia Therapeutics Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis
GlobeNewswire · 03/30 12:30
Intellia Therapeutics Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis
CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today that the Eur...
GlobeNewswire · 03/30 12:30
BRIEF-Intellia Therapeutics’ Investigational Crispr Treatment Ntla-2001 Receives European Union Orphan Drug Designation For Attr Amyloidosis
reuters.com · 03/30 12:08
Intellia Therapeutics’ NTLA-2001 wins EC's orphan drug status
Intellia Therapeutics (NTLA) announces that the European Commission ((EC)) has granted orphan drug designation to NTLA-2001, which is being developed as a treatment for transthyretin amyloidosis ((ATTR)), a rare condition
Seekingalpha · 03/30 11:48
Intellia Therapeutics Receives European Commission Orphan Drug Designation for NTLA-2001 to Treat Transthyretin Amyloidosis
MT Newswires · 03/30 10:00
Oppenheimer Issues a Hold Rating on Intellia Therapeutics (NTLA)
Oppenheimer analyst Jay Olson assigned a Hold rating to Intellia Therapeutics (NTLA) yesterday. The company's shares closed last Monday at $65.31.
SmarterAnalyst · 03/30 04:05
Intellia Therapeutics Presents New Data on Expanded Cell Engineering Capabilities Utilizing Base Editors
Intellia Therapeutics, Inc. (NASDAQ:NTLA) will present the first preclinical data set on its novel cytosine deaminase base editor technology at the seventh Cold Spring Harbor Laboratory (CSHL) virtual scientific meeting
Benzinga · 03/25 11:30
BRIEF-Intellia Therapeutics Presents Preclinical Proof Of Concept For CRISPR-Based In Vivo Editing Of Bone Marrow
reuters.com · 03/10 12:36
Intellia Therapeutics Highlights Presentation Of Preclinical Proof Of Concept For CRISPR-Based In Vivo Editing Of Bone Marrow At Keystone eSymposium
- Demonstrates the promise of Intellia's proprietary non-viral delivery system for in vivo genome editing of tissues outside the liver, with applications to inherited blood disorders such as sickle cell
Demonstrates the promise of Intellia's proprietary non-viral delivery system for in vivo genome editing of tissues outside the liver, with applications to inherited blood disorders such as sickle cell · 03/10 12:35
Intellia Therapeutics Presents Preclinical Proof of Concept for CRISPR-based In Vivo Editing of Bone Marrow at Keystone eSymposium
- Demonstrates the promise of Intellia’s proprietary non-viral delivery system for in vivo genome editing of tissues outside the liver, with applications to inherited blood disorders such as sickle cell disease - Observed durable, multidose editing of whol...
GlobeNewswire · 03/10 12:30
Biotech stocks are a buy — especially these 18 picks
The sector's recent pullback offers an chance to get into exciting areas of biotech research like gene editing and oncology at better prices.
marketwatch.com · 03/09 18:16
Chardan Capital Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)
Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Intellia Therapeutics (NTLA) on March 1. The company's shares closed last Friday at
SmarterAnalyst · 03/08 09:25
DJ Intellia Therapeutics Initiated at Outperform by JMP Securities
Dow Jones · 03/04 13:18
DJ Intellia Therapeutics Price Target Announced at $80.00/Share by JMP Securities
Dow Jones · 03/04 13:18
--Analyst Actions: JMP Securities Starts Intellia Therapeutics at Market Outperform With $80 Price Target
MT Newswires · 03/04 09:10
Webull provides a variety of real-time NTLA stock news. You can receive the latest news about Intellia through multiple platforms. This information may help you make smarter investment decisions.
About NTLA
Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company's division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company's subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.